Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
To confirm the non-inferiority of 75 mg risedronate tablets taken on 2 consecutive days per
month as compared to 5 mg risedronate tablets taken daily in increasing bone mass in lumbar
spine in postmenopausal women with osteoporosis.
To confirm the efficacy of 75 mg risedronate tablets taken on 2 consecutive days per month in
postmenopausal women with osteoporosis in increasing bone mass in proximal femur, femoral
neck and femoral trochanter and decreasing bone resorption.
To confirm general safety of 75 mg risedronate tablets taken on 2 consecutive days per month
as compared to 5 mg risedronate taken daily.